Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)

Eisai Co., Ltd.561 enrolled

Overview

Post-marketing surveillance to investigate the clinical safety and effectiveness in patients of all implantation of Gliadel with malignant glioma in the actual medical setting.

Study Type

OBSERVATIONAL

Enrollment

561

Conditions

Malignant Glioma

Interventions

No interventionOTHER

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion criteria: * All-patient of Gliadel implantation Exclusion criteria: * None

Locations (2)

Unnamed facility

Osaka, Osaka, Japan

Unnamed facility

Tokyo, Tokyo, Japan

Outcomes

Primary Outcomes

Number of Adverse Events/Serious Adverse Events

Time frame: Up to 3 months

Secondary Outcomes

Survival rate

Survival rate of subjects measured up to 1 year after implantation of Gliadel

Time frame: Up to 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.